International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blastsHervé Dombret, Hartmut Döhner, Rajat Kumar et al.|Blood|2015Cited by 1.2k
The QUAZAR AML-001 Maintenance Trial: Results of a Phase III International, Randomized, Double-Blind, Placebo-Controlled Study of CC-486 (Oral Formulation of Azacitidine) in Patients with Acute Myeloid Leukemia (AML) in First RemissionAndrew H. Wei, Gail J. Roboz, Hartmut Döhner et al.|Blood|2019Cited by 97
Azacitidine improves clinical outcomes in older patients with acute myeloid leukaemia with myelodysplasia-related changes compared with conventional care regimensJohn F. Seymour, Hervé Dombret, Hartmut Döhner et al.|BMC Cancer|2017Cited by 73